#United States #New York #Levi & Korsinsky #Pacira BioSciences #PCRX

Overview of Pacira BioSciences, Inc. Lawsuit

Pacira BioSciences, Inc. (NASDAQ: PCRX) is currently facing a class action lawsuit initiated by Levi & Korsinsky, LLP. This legal action aims to recover losses for investors associated with alleged securities fraud that occurred between August 2, 2023, and August 8, 2024. Investors are urged to respond by March 14, 2025, to potentially participate in the recovery process.

Background Details

The crux of the lawsuit revolves around a press release issued by Pacira on August 9, 2024, wherein the company disclosed the disappointing outcomes of a patent infringement lawsuit against eVenus. During this announcement, Pacira revealed that the U.S. Patent No. 11,033,495—the patent tied to its flagship product Exparel—was deemed invalid by the court. This invalidation fundamentally threatens the company's revenue stream since Exparel accounts for approximately 80% of Pacira's earnings.

Industry analysts have noted that the ruling raises significant concerns regarding the validity of Pacira's remaining patents. As a result, the marketplace may see an influx of generic alternatives that could further diminish Pacira's market share and escalate litigation costs in the future.

Following the news of the patent invalidation, the stock price of Pacira plummeted dramatically. The company's stock witnessed a staggering decline from $22.36 on August 8, 2024, to a low of $11.70 on August 9, marking a loss of over 47% in just one day. Such a rapid decrease in value has prompted investors adversely affected by these developments to consider their legal options.

Next Steps for Investors

For investors who experienced losses within the relevant timeframe, now is a crucial moment to act. The deadline to seek the appointment as lead plaintiff is set for March 14, 2025. However, it's important to note that participation in any potential recovery does not require one to serve as a lead plaintiff.

If you believe you are a member of the affected class of investors and want to explore your options for participation, you may do so without incurring any out-of-pocket expenses. Levi & Korsinsky, LLP has emphasized that affected class members may qualify for compensation without the risk of financial burden to themselves.

Why Choose Levi & Korsinsky?

With a reputable track record spanning over two decades, Levi & Korsinsky has successfully secured hundreds of millions of dollars for wronged shareholders. The firm specializes in complex securities litigation and claims, boasting a dedicated team of over 70 professionals committed to serving its clients. Moreover, their presence in ISS Securities Class Action Services' Top 50 Report for seven consecutive years underscores their prowess in the field.

Contact Information

Interested investors and shareholders who wish to pursue this matter may reach out to Levi & Korsinsky for further consultation:

• - Joseph E. Levi, Esq.

Email: [email protected]
Phone: (212) 363-7500

• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004

Conclusion

Because the implications of this lawsuit can significantly impact the future of Pacira BioSciences and its investors, affected parties should stay informed and consider their legal rights. The coming weeks are critical for those wishing to take part in this class-action suit as the specified deadline is fast approaching.